Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ: RNAZ )

3.520 -0.060 (-1.68%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,778
Open 3.620
Bid (Size) 3.450 (1)
Ask (Size) 3.600 (5)
Prev. Close 3.580
Today's Range 3.340 - 3.743
52wk Range 0.2160 - 9.890
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Gains Over 1%, General Mills Shares Fall
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
-45.48%
-45.48%
1 Month
+923.26%
+923.26%
3 Month
+442.71%
+442.71%
6 Month
+241.75%
+241.75%
1 Year
-53.68%
-53.68%

More News

Read More
Dow Surges 150 Points, US Current Account Deficit Widens In Q3
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into TransCode Therapeutics's Recent Short Interest
Via Benzinga
Why TransCode Therapeutics (RNAZ) Stock Is Diving
Via Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Transcode Therapeutics (RNAZ) Stock Is Moving
Via Benzinga
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.